CClinicalTrials.gg
TerminatedNCT05092646PhoenixUpdated Aug 7, 2026Results posted

Evaluating Intra-articular Injection of Axolotl Ambient Compared to Saline in Subjects With Ankle Osteoarthritis

A Phase 1/2 interventional study of Axolotl Ambient and "Drug/Placebo: 0.9% Normal Saline" in Ankle Osteoarthritis, sponsored by Axolotl Biologix. Terminated at 3 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Axolotl Biologix · Phase 1/2, Interventional, and Treatment

Why this study was terminated
This study was terminated by the Sponsor in December 2023 due to business considerations.
Phase
Phase 1/2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

A Double-blind, Multi-Center, Prospective, Randomized Placebo-controlled Pilot Study Evaluating Intra-articular Injection of Axolotl Ambient Compared to Saline in Subjects with Ankle Osteoarthritis. The goal of this pilot study and subsequent pivotal trial is to evaluate the safety and effectiveness of Axolotl Ambient intra-articular injection for ameliorating the pain and dysfunction associated with ankle OA.

Read the detailed description

This pilot study is a double-blind multi-center, prospective, randomized, placebo-controlled trial. Upon randomization, patients will receive 1 intraarticular injection of the investigational product or control fluid. Follow-up will be conducted at 4 weeks, 3 and 6 months, with 6 months serving as the primary endpoint. The primary outcomes will consist of patient reported outcomes of pain and functional assessment by the physician, specific to the foot and ankle. Subjects will be monitored for an additional 6 months to establish safety over a 1-year follow-up and evaluate the durability of benefit.

02

Conditions studied

  • Ankle Osteoarthritis

Browse trials for

Keywords

  • Osteoarthritis, Biologic, Amniotic Fluid
03

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Signed written informed consent
  2. Willing to be randomized to either the investigational or control group
  3. Male or female at least 18 years of age and less than 80
  4. Clinical diagnosis of symptomatic tibiotalar (ankle) OA (primary idiopathic OA or post-traumatic OA), modified K-L grade 1-3a
  5. One ankle is the most symptomatic lower extremity joint and the only lower extremity joint currently planned for treatment
  6. Willing and able to comply with all study requirements including all postoperative clinical and radiographic evaluations
  7. For women of childbearing potential (not post-menopausal for 12 months or surgically sterile), a urine pregnancy test with a negative result must be obtained at screening and on the day of procedure, prior to injection
  8. Male and female trial participants must commit to adequate birth control (e.g., surgically sterilized, oral contraceptive, two methods of barrier birth control, or abstinence) through the final follow-up
  9. Chronic ankle pain for ≥ 6 months
  10. SAOS Pain score ≥ 30 and ≤ 80 and AOS Function score ≥ 30 and ≤ 80
  11. Willing to discontinue all prescription and over-the-counter pain medications being used for ankle OA symptoms for the duration of the study, except for acetaminophen, which is not allowed for the 3 days preceding each scheduled follow-up visit and the day of the follow-up visit.

Exclusion criteria

Exclusion Criteria:

  1. Previously received intra-articular injections in the index joint of Axolotl Ambient, bone marrow aspirate concentrate (BMAC), platelet-rich plasma (PRP), or other biologic-based products within the last 12 months.
  2. Modified K-L Grade 3b or 4 osteoarthritis of the index joint
  3. Diagnosis of ipsilateral peri-articular arthritis (e.g. subtalar joint) that the investigator determines may significantly confound the study results
  4. Received intra-articular hyaluronic acid injection in the index joint within the last 6 months
  5. Received intra-articular steroid injection in the index joint within the last 3 months
  6. Prior major surgical repair or reconstruction of the ankle that the investigator determines may significantly confound the study results
  7. Baseline pain catastrophizing score ≥ 23
  8. Any surgery of the index ankle within the last 12 months
  9. Planned arthroscopy or other procedure on the ankle during the study
  10. Bilateral ankle OA requiring treatment of both ankles
  11. Pregnancy, breastfeeding, or woman of child-bearing potential not using adequate contraception
  12. Bone deficit
  13. Charcot foot disease
  14. Radiographic evidence of open epiphyses
  15. Systemic inflammatory condition
  16. Substantial vascular insufficiency
  17. Current treatment with anticoagulants
  18. Deformity in coronal, axial or sagittal plane greater the 30°
  19. Patients weighing less than 47 kg.
  20. BMI greater than 45 kg/m2
  21. Documented medical history of, or radiographic evidence of, a bone disease (e.g. severe osteoporosis or avascular necrosis) or other condition (e.g., osteolysis)
  22. Comorbidity that would limit the ability to administer any functional measurements
  23. Has at the time of injection, a systemic or local infection at the site of injection
  24. Medical condition, serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, would preclude participation in the study or potentially decrease survival or interfere with ambulation or rehabilitation (e.g., history of transient ischemic attack, stroke or liver disease)
  25. Known hypersensitivity to penicillin
  26. Known allergy to phenol red
  27. Currently receiving treatment with a drug known to interfere with bone or cartilage metabolism [e.g., systemic steroid therapy (topical steroid therapy is permissible), methotrexate]
  28. Medical condition requiring radiation, chemotherapy or immunosuppression
  29. Have an active history of malignancy (except for basal cell carcinoma of the skin)
  30. Has a history of autoimmune disease known to affect bone or cartilage. Examples include spondyloarthropathies (e.g., ankylosing spondylitis, Crohn's disease, and ulcerative colitis), Juvenile Arthritis, rheumatoid arthritis, Grave's disease, and Hashimoto's thyroiditis
  31. Has obvious or documented alcohol or illicit drug addictions
  32. Is a prisoner in a correctional institution/facility
  33. Actively involved in litigation or workman's compensation
  34. Has participated in clinical studies evaluating investigational devices, pharmaceuticals or biologics within 6 months of randomization
  35. Bedridden, confined to a wheelchair, or unable to walk 50 m without the help of a walker, crutches, or cane
  36. Is currently taking prescription pain medication for any conditions other than ankle osteoarthritis.
04

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Placebo comparator
    Control Group

    Single dose, 2.0 mL of 0.9% normal saline, administered via intra-articular injection administered to the affected tibiotalar joint.

    Drug: "Drug/Placebo: 0.9% Normal Saline"

  • Experimental
    Investigational Group

    Biological/Vaccine: Axolotl Ambient Axolotl Ambient is an allogeneic amniotic intraarticular injection therapy consisting of a growth factor and cytokine-rich fluid derived from human amnion cells. Other Names: • CA20

    Biological: Axolotl Ambient

Interventions

  • BiologicalAxolotl Ambient

    Axolotl Ambient is an allogeneic amniotic intra-articular injection therapy consisting of a growth factor and cytokine-rich fluid derived from human amnion cells.

    Also known as: CA20

  • Drug"Drug/Placebo: 0.9% Normal Saline"

    "Drug/Placebo: 0.9% Normal Saline"

05

What researchers measure

Primary outcomes

  1. Change From Baseline in Ankle Osteoarthritis Scale (AOS; 48 hr Recall) Pain Subscale

    The Ankle Osteoarthritis Scale (AOS) pain subscale goes from 0 (No pain) -100 (The worst imaginable).

    Time frame: 4-weeks, 3-months, and 6-months

  2. Change From Baseline for Ankle Osteoarthritis Scale (AOS; 48 hr Recall) Function Subscale

    The Ankle Osteoarthritis Scale (AOS) functions subscale goes from 0 (No difficulty) -100 (So difficult, unable).

    Time frame: 4-week, 3 Months, 6-months

  3. Change From Baseline for Foot and Ankle Outcome Score (FAOS) for Pain Subscale

    A score of 100 represents no pain. A score of 0 constant pain.

    Time frame: 4-weeks, 3-months, 6-months

  4. Change From Baseline for Foot and Ankle Outcome Score (FAOS) for Function Subscale

    100 represents perfect health and 0 represents extreme problems and complete functional limitation. .

    Time frame: 4-weeks, 3-months, 6-months

  5. Proportion of Patients Achieving Composite Clinical Success (CCS).

    CCS defined as a patient meeting all of the three following criteria: 1. Improvement in AOS (Pain and Function) or FAOS scores (Pain and ADL) of at least 20% from baseline 2. No surgical intervention or prescription pain medications for ankle OA 3. No treatment or procedure-related serious adverse events

    Time frame: 4-weeks, 3-months, 6-months

Secondary outcomes

  1. Incidence of Adverse Events

    Proportion of subjects experiencing at least (1) adverse events.

    Time frame: Post-procedure follow-up assessments: 4 weeks (+/-7days), 3 Months (+/- 14 days), 6 Months (+/- 30 days), 12 Months (+/- 60 days), and unscheduled visits (up to 19 months)

  2. FAOS Subscales Quality of Life (QoL)

    0 (most severe problems) to 100 (no problems/best possible qualify of life)

    Time frame: 4-week, 3-month, 6-month

  3. Visual Analog Scale (VAS) for Ankle Pain (Average During Last 48 Hours)

    100 millimeter scale 0mm - No Pain and 100mm - Worst Imaginable Pain

    Time frame: 4 weeks, 3-months, 6-months

  4. VAS Ankle Pain (Worst During Last 48 Hours)

    100 millimeter scale 0mm - No Pain and 100mm - Worst Imaginable Pain

    Time frame: 4-weeks, 3-months, 6-months

  5. EuroQOL-5 Dimension-5 Level (EQ-5D-5L) Quality of Life Scale

    0 to 100 scale - 0 the worst health you can imagine to 100 the best health you can imagine.

    Time frame: 4-weeks, 3-months, 6-months

  6. Working Status

    Not working, unrelated to ankle Not working, related to ankle Working with major limitations related to ankle Working without limitations related to ankle

    Time frame: Baseline, 4-weeks, 3-months, 6-months

  7. K-L Grade From Weightbearing X-ray at Baseline and 6 Months

    Grade 2 Definite osteophytes with mild to moderate joint space narrowing; early radiographic OA Grade 3a Significant osteophytes and joint space narrowing, but greater than 50% of the joint space remains preserved Grade 3b Severe joint space narrowing with less than 50% remaining joint space, approaching end-stage disease but not completely bone-on-bone Grade 4 Near complete or complete loss of joint space with substantial deformity (end-stage OA)

    Time frame: Baseline, 6-months

06

Results

Posted Aug 7, 2026

Participant flow

Participant flow — Overall Study
MilestoneControl GroupInvestigational Group
Started66
Completed22
Not completed44

Outcome measures

PrimaryChange From Baseline in Ankle Osteoarthritis Scale (AOS; 48 hr Recall) Pain Subscale

The Ankle Osteoarthritis Scale (AOS) pain subscale goes from 0 (No pain) -100 (The worst imaginable).

Time frame:
4-weeks, 3-months, and 6-months
Reported as:
Mean · score on a scale
Change From Baseline in Ankle Osteoarthritis Scale (AOS; 48 hr Recall) Pain Subscale
score on a scaleControl GroupInvestigational Group
4-weeks-7.0 ± 24.08-2.2 ± 23.32
3-months-11.7 ± 31.9719.3 ± 32.75
6-months-4.5 ± 12.476.3 ± 16.26
PrimaryChange From Baseline for Ankle Osteoarthritis Scale (AOS; 48 hr Recall) Function Subscale

The Ankle Osteoarthritis Scale (AOS) functions subscale goes from 0 (No difficulty) -100 (So difficult, unable).

Time frame:
4-week, 3 Months, 6-months
Reported as:
Mean · score on a scale
Change From Baseline for Ankle Osteoarthritis Scale (AOS; 48 hr Recall) Function Subscale
score on a scaleControl GroupInvestigational Group
4-weeks-13.3 ± 23.55-0.6 ± 23.51
3-months-14.2 ± 19.0512.3 ± 24.03
6-months-7.3 ± 7.748.7 ± 21.08
PrimaryChange From Baseline for Foot and Ankle Outcome Score (FAOS) for Pain Subscale

A score of 100 represents no pain. A score of 0 constant pain.

Time frame:
4-weeks, 3-months, 6-months
Reported as:
Mean · score on a scale
Change From Baseline for Foot and Ankle Outcome Score (FAOS) for Pain Subscale
score on a scaleControl GroupInvestigational Group
4-weeks10.0 ± 15.975.8 ± 22.33
3-months16.5 ± 14.60-13.0 ± 20.42
6-months8.8 ± 7.79-6.3 ± 12.66
PrimaryChange From Baseline for Foot and Ankle Outcome Score (FAOS) for Function Subscale

100 represents perfect health and 0 represents extreme problems and complete functional limitation. .

Time frame:
4-weeks, 3-months, 6-months
Reported as:
Mean · score on a scale
Change From Baseline for Foot and Ankle Outcome Score (FAOS) for Function Subscale
score on a scaleControl GroupInvestigational Group
4-weeks5.0 ± 8.692.8 ± 11.82
3-months8.5 ± 7.92-6.7 ± 10.97
6-months4.7 ± 2.50-3.3 ± 7.37
PrimaryProportion of Patients Achieving Composite Clinical Success (CCS).

CCS defined as a patient meeting all of the three following criteria: 1. Improvement in AOS (Pain and Function) or FAOS scores (Pain and ADL) of at least 20% from baseline 2. No surgical intervention or prescription pain medications for ankle OA 3. No treatment or procedure-related serious adverse events

Time frame:
4-weeks, 3-months, 6-months
Reported as:
Count of participants · Participants
Proportion of Patients Achieving Composite Clinical Success (CCS).
ParticipantsControl GroupInvestigational Group
4-weeks31
3-months31
6-months20
SecondaryIncidence of Adverse Events

Proportion of subjects experiencing at least (1) adverse events.

Time frame:
Post-procedure follow-up assessments: 4 weeks (+/-7days), 3 Months (+/- 14 days), 6 Months (+/- 30 days), 12 Months (+/- 60 days), and unscheduled visits (up to 19 months)
Reported as:
Count of participants · Participants
Incidence of Adverse Events
ParticipantsControl GroupInvestigational Group
Incidence of Adverse Events52
SecondaryFAOS Subscales Quality of Life (QoL)

0 (most severe problems) to 100 (no problems/best possible qualify of life)

Time frame:
4-week, 3-month, 6-month
Reported as:
Mean · score on a scale
FAOS Subscales Quality of Life (QoL)
score on a scaleControl GroupInvestigational Group
4-weeks12.5 ± 17.2711.4 ± 38.62
3-months14.5 ± 20.390.0 ± 13.00
6-months9.0 ± 18.602.0 ± 3.46
SecondaryVisual Analog Scale (VAS) for Ankle Pain (Average During Last 48 Hours)

100 millimeter scale 0mm - No Pain and 100mm - Worst Imaginable Pain

Time frame:
4 weeks, 3-months, 6-months
Reported as:
Mean · score on a scale
Visual Analog Scale (VAS) for Ankle Pain (Average During Last 48 Hours)
score on a scaleControl GroupInvestigational Group
4-weeks3.0 ± 43.69-0.6 ± 33.47
3-months-12.2 ± 40.9126.0 ± 29.00
6-months-15.3 ± 14.298.7 ± 15.82
SecondaryVAS Ankle Pain (Worst During Last 48 Hours)

100 millimeter scale 0mm - No Pain and 100mm - Worst Imaginable Pain

Time frame:
4-weeks, 3-months, 6-months
Reported as:
Mean · score on a scale
VAS Ankle Pain (Worst During Last 48 Hours)
score on a scaleControl GroupInvestigational Group
4-weeks-4.2 ± 32.852.2 ± 38.80
3-months-11.2 ± 39.2135.3 ± 35.92
6-months-13.7 ± 16.775.0 ± 10.00
SecondaryEuroQOL-5 Dimension-5 Level (EQ-5D-5L) Quality of Life Scale

0 to 100 scale - 0 the worst health you can imagine to 100 the best health you can imagine.

Time frame:
4-weeks, 3-months, 6-months
Reported as:
Mean · score on a scale
EuroQOL-5 Dimension-5 Level (EQ-5D-5L) Quality of Life Scale
score on a scaleControl GroupInvestigational Group
4-weeks8.3 ± 13.94-0.4 ± 21.87
3-months-0.2 ± 20.74-20.0 ± 21.79
6-months-5.7 ± 29.14-6.7 ± 7.64
SecondaryWorking Status

Not working, unrelated to ankle Not working, related to ankle Working with major limitations related to ankle Working without limitations related to ankle

Time frame:
Baseline, 4-weeks, 3-months, 6-months
Reported as:
Count of participants · Participants
Working Status
ParticipantsControl GroupInvestigational Group
Baseline — Not working, unrelated to ankle21
Baseline — Not working, related to ankle10
Baseline — Working with major limitations related to ankle01
Baseline — Working without limitations related to ankle34
4-weeks — Not working, unrelated to ankle11
4-weeks — Not working, related to ankle00
4-weeks — Working with major limitations related to ankle20
4-weeks — Working without limitations related to ankle34
3months — Not working, unrelated to ankle10
3months — Not working, related to ankle00
3months — Working with major limitations related to ankle21
3months — Working without limitations related to ankle32
6months — Not working, unrelated to ankle20
6months — Not working, related to ankle00
6months — Working with major limitations related to ankle21
6months — Working without limitations related to ankle22
SecondaryK-L Grade From Weightbearing X-ray at Baseline and 6 Months

Grade 2 Definite osteophytes with mild to moderate joint space narrowing; early radiographic OA Grade 3a Significant osteophytes and joint space narrowing, but greater than 50% of the joint space remains preserved Grade 3b Severe joint space narrowing with less than 50% remaining joint space, approaching end-stage disease but not completely bone-on-bone Grade 4 Near complete or complete loss of joint space with substantial deformity (end-stage OA)

Time frame:
Baseline, 6-months
Reported as:
Count of participants · Participants
K-L Grade From Weightbearing X-ray at Baseline and 6 Months
ParticipantsControl GroupInvestigational Group
baseline Day 0 — Grade 2 Definite osteophytes with mild to moderate joint space narrowing; early radiographic OA42
baseline Day 0 — Grade 3a13
baseline Day 0 — Grade 3b10
baseline Day 0 — Grade 400
6 Month — Grade 2 Definite osteophytes with mild to moderate joint space narrowing; early radiographic OA30
6 Month — Grade 3a11
6 Month — Grade 3b00
6 Month — Grade 400

Adverse events

Collected over 19 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Control Group0/6 (0%)0/6 (0%)5/6 (83.3%)
Investigational Group0/6 (0%)0/6 (0%)2/6 (33.3%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventControl GroupInvestigational Group
Back PainMusculoskeletal and connective tissue disorders3/60/6
Foot and Ankle PainMusculoskeletal and connective tissue disorders3/60/6
Hip PainMusculoskeletal and connective tissue disorders2/60/6
Back InjuryMusculoskeletal and connective tissue disorders0/61/6
Left Hip OsteoarthritisMusculoskeletal and connective tissue disorders0/61/6
Muscle SpasmsMusculoskeletal and connective tissue disorders1/60/6
Knee PainMusculoskeletal and connective tissue disorders1/60/6
Foot NumbnessMusculoskeletal and connective tissue disorders1/60/6
Wrist PainMusculoskeletal and connective tissue disorders1/60/6
BronchitisRespiratory, thoracic and mediastinal disorders1/60/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Control GroupInvestigational GroupTotal
<=18 years000
Between 18 and 65 years6612
>=65 years000
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Control GroupInvestigational GroupTotal
Male or Female6612
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Control GroupInvestigational GroupTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)Control GroupInvestigational GroupTotal
United States6612
07

Study locations

3 sites
  • Injury Care Research
    Boise, Idaho 83713, United States
  • Orthopedic Specialists of Louisiana
    Shreveport, Louisiana 71101, United States
  • OrthoCarolina Foot and Ankle Institute
    Charlotte, North Carolina 28207, United States
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Apr 13, 2022

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Registry details

Key details

Study ID
NCT05092646
Lead sponsor
Axolotl Biologix
Responsible party
Sponsor
First posted
Oct 25, 2021
Start date
Dec 1, 2021
Primary completion
Nov 10, 2023
Completion
Nov 10, 2023
Results posted
Aug 7, 2026
Last update
Aug 7, 2026

Study contacts

Robert S. Kellar, PhD
study director · Chief Science Officer (CSO)
Aaron J. Tabor, PhD, CTBS
study director · V.P. of Clinical Operations

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion